Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | USP5 | P45974 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | BCL9 | O00512 | 1/20 | 0.38 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15841672 | 1.00 | CCR5 (0.44) | CCR5AKR1C3AKR1C1MEN1KMT2A | |
| SCHEMBL1349430 | 0.84 | AKR1C3 (0.44) | CCR5AKR1C3AKR1C1USP5GAA | |
| SCHEMBL1347177 | 0.84 | AKR1C3 (0.44) | CCR5AKR1C3AKR1C1USP5GAA | |
| SCHEMBL1349434 | 0.84 | AKR1C3 (0.44) | CCR5AKR1C3AKR1C1USP5GAA | |
| SCHEMBL1347178 | 0.84 | AKR1C3 (0.44) | CCR5AKR1C3AKR1C1USP5GAA | |
| SCHEMBL1347181 | 0.84 | AKR1C3 (0.44) | CCR5AKR1C3AKR1C1USP5GAA | |
| SCHEMBL1349356 | 0.81 | USP2 (0.45) | CCR5AKR1C3AKR1C1USP5LMNA | |
| SCHEMBL1348822 | 0.81 | USP2 (0.45) | CCR5AKR1C3AKR1C1USP5LMNA | |
| SCHEMBL1346809 | 0.79 | ALDH1A1 (0.40) | AKR1C3AKR1C1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1349188 | 0.79 | PKM (0.47) | MEN1KMT2AUSP5PKMBCL9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2288594-B1 | IMIDAZOLIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-07-02 | — | — | EP | claimed |
| EP-2288594-A1 | IMIDAZOLIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-03-02 | — | — | EP | claimed |
| US-20090312382-A1 | NOVEL IMIDAZOLIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-17 | — | — | US | claimed |
| WO-2009150109-A1 | IMIDAZOLIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-17 | — | — | WO | claimed |
| EP-2288594-B1 | IMIDAZOLIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-07-02 | — | — | EP | disclosed |
| US-8063088-B2 | Imidazolidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-11-22 | — | — | US | disclosed |
| EP-2288594-A1 | IMIDAZOLIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-03-02 | — | — | EP | disclosed |
| US-20090312382-A1 | NOVEL IMIDAZOLIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-17 | — | — | US | disclosed |
| WO-2009150109-A1 | IMIDAZOLIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312382-A1 | NOVEL IMIDAZOLIDINE DERIVATIVES | NR1H2, NR1H3, NR1D2 | CCR5 321/4885AKR1C3 844/4885AKR1C1 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.